 |
5-[8-methyl-9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6yl]-2-pyrimidinamine |
|---|---|
| Trade Name | |
| Orphan Indication | Malignant pleural mesothelioma |
| USA Market Approval | USA |
| USA Designation Date | 2015-02-10 00:00:00 |
| Sponsor | Verastem, Inc.;117 Kendrick Street, Suite 500;Needham, Massachusetts, 02494 |
